Literature DB >> 12467312

The benefit of using two techniques for sentinel lymph node mapping in breast cancer.

Armando Sardi1, Ethan Spiegler, Jean Colandrea, David Frishberg, Hardeep Sing, Patricia Regan, Adil Totoonchie, Deepak Merchant, Stephen Hochuli, Viney Setya, John A Singer.   

Abstract

Sentinel lymph node (SLN) mapping has revolutionized the way we stage breast cancer. A blue dye technique (BD) and the use of a radiotracer with the assistance of a gamma-detecting probe (GDP) have been used for the identification of the sentinel nodes. Some groups have suggested that only one technique is necessary. The reported false negative rates have been 0 to 12 per cent and success rates as low as 65 per cent. We have prospectively evaluated these techniques and have used both for the identification of the SLN. Ten surgeons participated in this study. From April 1998 through May 1999, 58 patients underwent SLN mapping followed by an axillary lymph node dissection. After the injection of 0.3 to 1.96 mCi of filtered sulfur colloid diluted to 4 mL all patients had preoperative lymphoscintigraphy. Five minutes before surgery 3 to 5 mL of isosulfan blue was injected around the tumor or tumor bed. Even though preoperative lymphoscintigraphy identified an SLN in 35 patients (63%) successful intraoperative detection of an SLN was possible using both techniques in 53 patients (91%). The SLN was detected by the BD and the GDP in 37 (65%) and 45 (80%) respectively. Nineteen patients (33%) were positive for metastatic disease in the axilla. Twenty-two (19%) of 113 SLNs removed were positive for disease. All cases of metastatic disease in the axilla were detected by the mapping technique. False negative rate was 0 per cent. In 11 patients the only positive node was the sentinel node (58%). Furthermore six (32%) patients were upstaged by the use of immunostains for cytokeratin. Twenty-two positive SLNs were detected in the 19 patients. The positive lymph node was identified only by BD in four patients (21%), only by GDP in six patients (31%), and by both techniques in nine patients (47%). We conclude that if only one technique had been used the false negative rate could have been as high as 32 per cent. Both techniques must be used to obtain a low false negative rate and high yield in the identification of the SLN.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12467312

Source DB:  PubMed          Journal:  Am Surg        ISSN: 0003-1348            Impact factor:   0.688


  9 in total

1.  Sentinel lymph node detection by means of indocyanine green using the Karl Storz VITOM® fluorescence camera: a comparison between primary sentinel lymph node biopsy versus sentinel lymph node biopsy after neoadjuvant chemotherapy.

Authors:  Petronilla Staubach; Anton Scharl; Atanas Ignatov; Olaf Ortmann; Elisabeth C Inwald; Thomas Hildebrandt; Michael Gerken; Monika Klinkhammer-Schalke; Sophia Scharl; Thomas Papathemelis
Journal:  J Cancer Res Clin Oncol       Date:  2020-11-23       Impact factor: 4.553

2.  Clinicopathologic factors associated with false-negative sentinel lymph-node biopsy in breast cancer.

Authors:  Robert C G Martin; Anees Chagpar; Charles R Scoggins; Michael J Edwards; Lee Hagendoorn; Arnold J Stromberg; Kelly M McMasters
Journal:  Ann Surg       Date:  2005-06       Impact factor: 12.969

3.  The false-negative rate of sentinel node biopsy in patients with breast cancer: a meta-analysis.

Authors:  Sarah Pesek; Taka Ashikaga; Lars Erik Krag; David Krag
Journal:  World J Surg       Date:  2012-09       Impact factor: 3.352

4.  Breast cancer sentinel lymph node mapping using near-infrared guided indocyanine green in comparison with blue dye.

Authors:  Wenbin Guo; Li Zhang; Jun Ji; Wei Gao; Jintao Liu; Meng Tong
Journal:  Tumour Biol       Date:  2013-12-05

5.  Evaluation of the benefit of using blue dye in addition to indocyanine green fluorescence for sentinel lymph node biopsy in patients with breast cancer.

Authors:  Wenbin Guo; Li Zhang; Jun Ji; Wei Gao; Jintao Liu; Meng Tong
Journal:  World J Surg Oncol       Date:  2014-09-20       Impact factor: 2.754

6.  Use of Fluorescence Imaging in Combination with Patent Blue Dye versus Patent Blue Dye Alone in Sentinel Lymph Node Biopsy in Breast Cancer.

Authors:  Meng Tong; Wenbin Guo; Wei Gao
Journal:  J Breast Cancer       Date:  2014-09-30       Impact factor: 3.588

7.  Nonvisualization of sentinel node by lymphoscintigraphy in advanced breast cancer.

Authors:  Brian Wosnitzer; Rosna Mirtcheva; Munir Ghesani
Journal:  Radiol Case Rep       Date:  2015-11-06

8.  10 % fluorescein sodium vs 1 % isosulfan blue in breast sentinel lymph node biopsy.

Authors:  Lidong Ren; Zhao Liu; Mengdi Liang; Li Wang; Xingli Song; Shui Wang
Journal:  World J Surg Oncol       Date:  2016-11-03       Impact factor: 2.754

9.  Sentinel Lymph Node Biopsy in Breast Cancer Patients by Means of Indocyanine Green Using the Karl Storz VITOM® Fluorescence Camera.

Authors:  Thomas Papathemelis; Evi Jablonski; Anton Scharl; Tanja Hauzenberger; Michael Gerken; Monika Klinkhammer-Schalke; Matthias Hipp; Sophia Scharl
Journal:  Biomed Res Int       Date:  2018-03-26       Impact factor: 3.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.